Pfizer, a leading U.S. pharmaceutical company, announced plans to acquire Metsera, a manufacturer of obesity and heart‑disease treatments, in a deal valued at $4.9 billion. The acquisition is intended to broaden Pfizer’s portfolio by entering the rapidly growing market for obesity medicines. Pfizer CEO Albert Bourla said, “Obesity is a large and growing space with over 200 health conditions associated with it,” emphasizing that the purchase aligns with the company’s strategy to invest in the most impactful opportunities and to expand into this key therapeutic area.
Under the terms of the agreement, Pfizer will buy all outstanding shares of Metsera common stock for $47.50 per share, with the transaction expected to close in the final quarter of this year. The move comes as pharmaceutical firms increasingly focus on obesity and diabetes treatments, spurred by the success of drugs such as Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Zepbound. Pfizer’s decision is notable given its history of developing innovative therapies, including one of the first COVID‑19 vaccines.
Although Pfizer’s stock has fallen since the pandemic—from $58 a share in December 2021 to $24 at the close of trading on Friday in New York—its shares rose 1.6 percent in electronic trading before Wall Street opened on Monday. Metsera’s shares, by contrast, jumped 60 percent following the announcement.
The acquisition underscores the growing importance of the obesity‑treatment market, which the World Health Organization identifies as a major risk factor for numerous health conditions. As demand for effective therapies rises, pharmaceutical companies are investing heavily in research and development to address this pressing health issue. With the deal’s completion, Pfizer is poised to play a significant role in this expanding market, marking a notable development in its strategic growth plans.
Comments are closed for this story.